Outcomes of SGLT2 Inhibitors Use in Diabetic Renal Transplant Patients Fatima AlKindi a, *, Hanan L. Al-Omary b , Qutaiba Hussain c , Mohamed Al Hakim c , Ahmed Chaaban c , and Yousef Boobes c a Internal Medicine Department, Tawam Hospital, Al-Ain, United Arab Emirates; b Medical College, University of Baghdad, University of Baghdad, Iraq; and c Nephrology Division, Tawam Hospital, Al-Ain, United Arab Emirates ABSTRACT Sodium-glucose cotransporter 2 (SGLT2) inhibitors are newly introduced hypoglycemic drugs that work by inhibiting glucose reabsorption at proximal renal tubules. The use of SGLT2 inhibitors in nontransplant diabetic patients with or without cardiovascular disease has well- established efficacy and safety. The risks of renal graft dysfunction and urinary tract in- fections might be the limiting factors for their use in renal transplant patients. Data regarding the safety and long-term efficacy of SGLT2 inhibitors use in diabetic renal transplant patients is scanty. The aim of the study is to report our experience with use of SGLT2 inhibitors in 8 diabetic renal transplant patients supported by literature review. Eight diabetic renal transplant patients were recruited from Tawam hospital during the period between June 2016 and January 2019. Demographic, clinical, and laboratory data were collected and analyzed. Adding SGLT2 resulted in significant decrease in hemoglobin A1c and body mass index after 12 months of treatment. There was significant negative correlation between the duration of treatment with SGLT2 and hemoglobin A1c. Diabetic renal transplant patients with stable kidney function had better glycemic control with use of SGLT2 inhibitors. There was no deterioration of kidney function and risk of recurrent urinary tract infection was low. D IABETES mellitus and new-onset diabetes after transplantation is prevalent among renal transplant patients [1]. Sodium-glucose cotransporter 2 (SGLT2) in- hibitors are newly introduced hypoglycemic drugs that work by inhibiting glucose reabsorption at proximal renal tubules. The use of SGLT2 inhibitors in nontransplant diabetic patients with or without cardiovascular disease has well- established efficacy and safety [2,3]. Recent systematic review and meta-analysis demonstrated long-term renal protective effects of SGLT2 inhibitors in diabetic patients with chronic kidney disease [4]. However, the Food and Drug Administration has issued alerts regarding increased acute kidney injury risk with 2 of them, canagliflozin and dapagli- flozin. The risks of renal graft dysfunction and urinary tract infections (UTIs) might be the limiting factors for their use in renal transplant patients. Data regarding the safety and long- term efficacy of SGLT2 inhibitors use in diabetic renal transplant patients is scanty. We aimed to study the short- term safety and efficacy of SGLT2 inhibitors in diabetic renal transplant patients supported by literature review. PATIENTS AND METHOD A retrospective chart review study was conducted at Tawam hospital (tertiary hospital in Al-Ain, United Arab Emirates) over 2 years from June 2016 until January 2019. We included all diabetic renal transplant patients who were started on SGLT2 inhibitors during the study period. The patients were followed up regularly in renal transplant and endocrine clinics, and SGLT2 inhibitors were added by team members after explaining the potential side effects. Statement of Ethics: Ethical approval was obtained from the institutional review board of Tawam Hospital. Disclosure Statement: The authors report no conflicts of interest. Funding Sources: The study was not funded and no research grants were received. *Address correspondence to Fatima AlKindi, Internal Medicine, Tawam Hospital, United Arab Emirates. E-mail: dr.fkendi@gmail. com ª 2019 Elsevier Inc. All rights reserved. 230 Park Avenue, New York, NY 10169 0041-1345/19 https://doi.org/10.1016/j.transproceed.2019.11.007 Transplantation Proceedings, XX, 1e4 (2019) 1